Jean-richard R. Eveillard
Brest, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 30 publications
Teclistamab in Elderly Patients With Relapsed/Refractory Multiple Myeloma: A Subgroup Analysis of the French RetrosTECtive Cohort.
Journal: EJHaem
Published: October 16, 2025
35 years of academic trials focusing on high-dose therapy and autologous stem cell transplantation: the Intergroupe Francophone du Myélome (IFM) experience.
Journal: Blood cancer journal
Published: July 07, 2025
Consequences and impacts of PEG-IFNα2a shortage: first lessons from a MPN French center.
Journal: Annals of hematology
Published: June 24, 2025
Late toxicity and long-term efficacy of first-line bendamustine and rituximab combination in patients with Waldenström macroglobulinemia.
Journal: Leukemia
Published: June 03, 2025
A new pitfall in potassium testing: A case series of false elevation of hemolysis index in the presence of monoclonal protein.
Journal: Clinica chimica acta; international journal of clinical chemistry
Published: February 28, 2025
Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial.
Journal: The Lancet. Oncology
Published: April 05, 2024
Acquired pseudoxanthoma elasticum-like syndrome and pyruvate kinase deficiency: a case of iron overload?
Journal: European journal of dermatology : EJD
Published: August 18, 2023
Assessment of the lipemia index determined by the Atellica CH 930 analyzer for the detection of monoclonal immunoglobulins.
Journal: Clinical chemistry and laboratory medicine
Published: August 01, 2023
ANCHOR: melflufen plus dexamethasone and daratumumab or bortezomib in relapsed/refractory multiple myeloma: final results of a phase I/IIa study.
Journal: Haematologica
Published: May 08, 2023
Heterogeneity in long-term outcomes for patients with Revised International Staging System stage II, newly diagnosed multiple myeloma.
Journal: Haematologica
Published: December 22, 2021
Ki67 Immunohistochemical Expression Level ≥70%, Bulky Presentation ≥7.5 cm, Meningeal Lymphomatosis, and Interim PET ΔSUVmax After 4 Treatment Cycles <71% as Parts of a Practical Scoring System to Predict Progression-Free Survival and Overall Survival in Diffuse Large B-Cell Lymphoma.
Journal: Frontiers in nuclear medicine
Published: December 05, 2021
Last Updated: 09/26/2026